Compare LyondellBasell Industries NV (LYB) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
LyondellBasell Industries NV vs Neurocrine Biosciences Inc — how do they compare? LyondellBasell Industries NV trades at $63.3 (market cap $20.67B), while Neurocrine Biosciences Inc trades at $158.84 (market cap $16.46B). The key difference: LyondellBasell Industries NV is the larger of the two by market cap, and LyondellBasell Industries NV pays a 6.44% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| LYB | NBIX | |
|---|---|---|
Market Cap | $20.67B | $16.46B |
Sector | Basic Materials | Health |
52-Week High | $82.38 | $185.50 |
52-Week Low | $42.28 | $123.10 |
Enterprise Value | $32.26B | $16.48B |
Dividend Yield | 6.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LyondellBasell Industries (LYB) trades at $62.65, up 5.13% today, reflecting positive momentum following a strong Q2 2026 earnings beat. The stock shows bullish technical signals with moving averages supporting an uptrend, while fundamentals reveal a mixed picture with declining revenue but improving quarterly EPS. Recent news highlights supply disruptions supporting margins and analyst upgrades after the earnings report.
The outlook is cautiously optimistic with a consensus price target of $70.56, suggesting upside potential. Key opportunities include operational leverage from cost cuts and favorable petrochemical supply dynamics, but risks persist from volatile commodity markets and negative net income margins. Institutional sentiment leans positive with recent stake increases.
Neurocrine Biosciences (NBIX) trades at $158.89, down 3.66% in the past 24 hours, reflecting near-term bearish technical signals. The stock shows strong fundamentals with Q2 2026 revenue growth of 39% year-over-year to $959 million and a net income margin of 20.91%. Recent news highlights include positive clinical data for INGREZZA and the initiation of a Phase 1 study for a GLP-1/GIP/glucagon receptor triple agonist, though safety concerns were raised for Vykat XR in Prader-Willi Syndrome.
The outlook remains positive given robust earnings beats, raised 2026 sales guidance, and a consensus price target of $208.82 implying significant upside. Risks include clinical trial setbacks, competitive pressures, and regulatory scrutiny. Analyst sentiment is strongly bullish with 86% buy ratings, supporting a growth-oriented investment case amid near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About LyondellBasell Industries NV
LyondellBasell Industries NV is a petrochemical producer with operations in the U.S. and Europe. It operates in six segments: Olefins and Polyolefins-Americas (O&P-Americas), Olefins and Polyolefins-Europe, Asia, International (O&P-EAI), Intermediates and Derivatives (I&D), Advanced Polymer Solutions (APS), Refining and Technology. The company is a major producer of polyethylene, the world's largest producer of polypropylene, and the second- largest producer of propylene oxide. Its chemicals are used in various consumer and industrial end products. Substantially, all of the company's revenue is derived from product sales.
Read more on LYB →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
